***Mycobacterium avium* complex (MAC) genomics and transmission in a London**

hospital

Andries J van Tonder[1], Huw C Ellis[2,3], Colin P Churchward[3], Kartik Kumar[2,3], Newara

Ramadan[4], Susan Benson[4], Julian Parkhill[1*], Miriam F Moffatt¶[3], Michael R

Loebinger¶[2,3], William OC Cookson¶[2,3*]

[1]Department of Veterinary Medicine, University of Cambridge, Cambridge

[2] Host Defence Unit, Department of Respiratory Medicine, Royal Brompton Hospital,

Guy's and St Thomas' NHS Foundation Trust, London

[3]National Heart and Lung Institute, Imperial College London, London

[4]Department of Microbiology, Royal Brompton Hospital, Guy's and St Thomas' NHS

Foundation Trust, London

* Corresponding authors: jp369@cam.ac.uk, w.cookson@imperial.ac.uk

¶ Contributed equally

Abstract

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental microorganisms

and opportunistic pathogens in individuals with pre-existing lung conditions such as

cystic fibrosis (CF) and non-CF bronchiectasis (BX).   Whilst recent studies of

Mycobacterium abscessus have identified transmission within single CF centres as

well as nationally and globally, transmission of other NTM species is less well studied.

We sequenced 996 Mycobacterium avium complex (MAC) isolates from CF and non-

CF patients at the Royal Brompton Hospital (RBH), London. Genomic analysis was

used to analyse local transmission. Epidemiological links were identified from patient

records. These and previously published genomes were used to characterise global

population structures. Analysis of the three predominant MAC species identified

putative transmission clusters that contained patients with CF, BX and other lung

conditions, although few epidemiological links could be identified. For *M. avium*,

lineages were largely limited to single countries, whilst for *M. chimaera*, global

transmission clusters previously associated with heater cooler units (HCUs) were

found. However, the immediate ancestor of the lineage causing the major HCU-

associated outbreak was a lineage already circulating in patients with pre-existing

lung conditions. CF and non-CF patients shared transmission chains even in the

presence of CF patient-focussed hospital control measures, although the lack of

epidemiological links suggested that most transmission is indirect and may involve

environmental intermediates or else asymptomatic carriage in the wider population.

The major HCU-associated *M. chimaera* lineage being derived from an already

circulating lineage, suggests that HCUs, while being responsible for a major global

transmission event, are not the sole vector nor the ultimate source of this wider

patient-infecting lineage. Future studies should include sampling of environmental

reservoirs and potential asymptomatic carriers.

Author summary

Whilst recent studies in *Mycobacterium abscessus* have identified transmission within

single CF centres as well as nationally and globally, the transmission dynamics

between CF and non-CF patients has not yet been comprehensively examined in the

Mycobacterium avium complex (MAC). We believe this is the first study to use a well-sampled longitudinal isolate dataset, that includes both CF and non-CF patients from a single hospital setting, to investigate transmission of MAC species. We identified transmission clusters in the three predominant MAC species circulating in the hospital and showed that these included both CF and non-CF patients. We then incorporated isolates from previous studies to examine the global population structure of MAC species and showed that for *M. avium* there were UK-specific lineages circulating amongst patients, whilst for *M. chimaera* we could identify global lineages associated with HCUs. For the first time, we also show that the predominant HCU-associate lineage is likely derived from already circulating lineages associated with patients with respiratory diseases. Our study shows the value of integrating whole genome sequencing with epidemiological data to perform high-resolution molecular analyses to characterise MAC populations and identify transmission clusters. Knowledge of putative transmission networks can improve responses to outbreaks and inform targeted infection control and clinical practice.

Introduction

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental microorganisms found in soil and water and are considered opportunistic pathogens in humans. Individuals with pre-existing genetic or acquired lung diseases such as cystic fibrosis (CF), non-CF bronchiectasis (BX) and chronic obstructive pulmonary disease (COPD) are more prone to NTM disease although individuals with no known immune dysfunction can also present with NTM infections (1–3). Symptoms of NTM pulmonary disease are variable but most patients will develop a chronic cough and

other symptoms may include fatigue, sputum production, chest pain, breathlessness,

fever and weight loss (1). Globally, disease due to NTM infections is increasing in

prevalence. For example, the estimated prevalence of NTM disease in the United

States of America (USA) rose from 2.4 cases/100,000 in the early 1980s to 15.2

cases/100,000 in 2013 (4), whilst in the United Kingdom (UK) the prevalence rose

from 0.9 cases/100,000 to 2.9 cases/100,000 between 1995 and 2006 (5). NTM

infections may be progressive and treatment requires prolonged multi-drug therapy

(6) and is often unsuccessful due to an absence of antimicrobial agents with low

toxicity and effective *in vivo* activity against NTM species (1).

A number of NTM species including *Mycobacterium abscessus* and members of the

Mycobacterium avium complex (MAC), notably *M. avium* and *M. intracellulare*, have

emerged as major respiratory pathogens in the past three decades (7–9). Another

member of the MAC, *M. chimaera*, has also been implicated in numerous global

infections associated with cardiothoracic surgery with the source of infections linked

to heater-cooler units (HCUs) contaminated during their manufacture (10–12).

Until recently the prevailing hypothesis was that infections caused by NTM were due

to independent acquisitions from environmental sources such as soil, contaminated

drinking water distribution systems and household plumbing. Recent studies of *M.*

abscessus in CF patients have however identified indirect patient-patient

transmission within a single CF centre as well as the presence of globally circulating

clones of *M. abscessus* amongst CF patients worldwide (13–17). An observational

study of *M. abscessus,* across England revealed that these dominant clones are also

found in patients with other chronic respiratory diseases. The study however was

unable to identify epidemiological links for most closely-related isolates, suggesting

environmental acquisition may be involved (18). Another recent study of *M.*

abscessus has demonstrated that transmission networks may involve both people

with CF and those without, and that these transmission networks are global. It is

therefore likely that transmission is complex, involving multiple patient cadres as well

as environmental intermediates (19). In the special case of *M. chimaera*, the high level

of genetic similarity between sequenced *M. chimaera* isolates collected from patients,

HCUs and the factory of origin suggested a point source contamination during

manufacture causing global distribution followed by localised transmission (12).

To date, little work has been done to examine whether similar patterns of transmission

in the MAC are occurring between patients with CF, BX or other chronic respiratory

diseases. Using a large collection of longitudinal isolates collected from patients

attending the Royal Brompton Hospital (RBH) in London, the aims of this study were

to characterise the population structure of MAC; to identify potential transmission

chains involving patients with CF and other non-CF lung conditions; and to place the

RBH isolates in a global context using previously published genomes.

Methods

Consent/ethics

The study (access to patients' clinical data) was approved by the NHS Health

Research Authority (HRA) and Health and Care Research Wales (HCRW) (REC

reference 21/HRA/2554).

Data collection

Clinical data pertaining to patients from whom NTM cultures were isolated were collected from electronic health records at the RBH. Data included patients' sex, age at the time of first positive NTM culture, height, weight, lung function test results, comorbidities, medication history and date of death (where applicable). Anonymization was undertaken by removing personal data, including patients' hospital numbers, prior to analysis.

Sample collection

Isolates were collected from patients attending the respiratory inpatient and outpatient clinics of the RBH between January 2013 and April 2016. The RBH routinely archive all mycobacterial isolates cultured from their patients and this archive was used without selection as the basis for the study.

Culturing, DNA extraction and sequencing

Sputum samples were grown in BBL MGIT media (BD) in a Bactec MGIT 960 (BD) until the system indicated Mycobacterial growth. Species confirmation was performed using the HAIN GenoType System. Confirmed MAC cultures were regrown from bead stock cultures in BBL MGIT media (BD) in a Bactec MGIT 960 (BD) until the system indicated growth. In the absence of growth, DNA was extracted from the bead stock. DNA extractions were performed as previously described (https://dx.doi.org/10.17504/protocols.io.bf28jqhw). A total of 1189 DNA extracts were sequenced by the core pipeline teams at the Wellcome Sanger Institute. The

Illumina Hiseq X10 platform was used to generate 2 x 150 bp paired-end reads. Raw

sequencing reads were deposited at the European Nucleotide Archive under project

PRJEB21813. All accessions used in this project are listed in S1 Table.

Sequence QC, mapping and phylogenetics

Basic quality control metrics for the raw sequence data were generated using FastQC

v0.11.9 (20).　Sequence reads with similarity to *Mycobacterium* species were

identified using Kraken v0.10.6 (21) and Bracken v1.0 (22). Samples with < 70%

reads mapping to a *Mycobacterium* species were excluded from further analyses (n

= 116). Seven isolates not belonging to the MAC (*M. abscessus, M. chelonae, M.*

simiae) were removed from the dataset. Sequence reads for each species were

trimmed using Trimmomatic v0.33 (23) and mapped to appropriate references (Table

A in S1 Data) using BWA mem v0.7.17 (minimum and maximum insert sizes of 50 bp

and 1000 bp respectively) (24). Single nucleotide polymorphisms (SNPs) were called

using SAMtools v1.2 mpileup and BCFtools v1.2 (minimum base call quality of 50 and

minimum root squared mapping quality of 30) as previously described (25). Samples

with reads that mapped to < 80% of the reference were excluded (n = 70). Variant

sites were extracted from the resulting alignments using snp-sites v2.5.1 (26). Whole

species maximum likelihood phylogenetic trees were built using IQ-tree v1.6.5

accounting for constant sites (-fconst; determined using snp-sites -C) with the built-

in model testing (-m MFP) to determine the best phylogenetic model and 1000

ultrafast bootstraps (-bb 1000) (27).

For higher-resolution phylogenies within fastBAPS lineages, recombinant regions

were identified and removed from alignments using GUBBINS (28) and new

phylogenetic trees were constructed as described above. Pairwise SNP distances

were calculated for all pairs of isolates using pairsnp (29).

Global collections

To provide context for each the isolates sequenced for each species in this study,

datasets consisting of published sequenced isolates were assembled (S2 Table)

(12,30–49). Sequence data were downloaded from the European Nucleotide Archive

(ENA) and trimmed; Sample QC, mapping and phylogenetic tree construction were

performed as detailed above. Only the first isolate from each patient was included

from the RBH isolates for each species/subspecies.

Genome assemblies

A previously published pipeline was used to produce annotated assemblies (50).

Briefly, sequence reads were assembled with spades v 3.10.10 (51) and assemblies

were improved by first scaffolding the assembled contigs using SSPACE v2.0 (52)

and filling the sequence gaps with GapFiller v1.11 (53).

Transmission and epidemiological linkage

Genomic lineages were identified using fastBAPS (54) and new alignments were

created for lineages $\geq$ ten isolates by aligning sequence reads for included isolates

against the assembly that had the smallest number of contigs (using the method

described above). In order to calculate a pairwise SNP threshold to determine

putative transmission clusters within each genomic lineage, pairwise SNP distances

for all isolates for each species in the RBH datasets were calculated. Using a

previously described method (55), the transmission threshold for each species,

regardless of lineage, was calculated by taking the 95th percentile of the maximum

within-patient isolate pairwise SNP distances for all patients and adding twice the

number of mutations expected to occur in a six month period. To account for excess

within-patient diversity observed in the *M. chimaera* FB1 and *M. avium* subsp. *avium*

FB14 lineages (Fig A in S1 Data), pairwise SNP distances greater than 25 and 50

(assumed to result from infection with multiple lineages) were removed respectively

before the above calculations were performed. Based on these results, the R library

iGRAPH (56,57) and pairwise SNP thresholds of 16 (*M. intracellulare* and *M. avium*

subsp. *hominissuis*), 30 (*M. chimaera*) and 58 SNPs (*M. avium* subsp. *avium*) were

used to calculate putative transmission clusters in each genomic lineage. Finally, in

order to identify possible epidemiological links between patients infected within the

same transmission clusters, hospital stay records were examined for epidemiological

contacts. The latter were defined as patients attending the same ward on the same

day up to one year prior to the collection of the first sequenced isolate.

Results

Patient demographics

The median age and BMI of the 354 patients included in the study was 56 years

(range 5 - 93) and 22.5 (range 13.4 – 43.4) respectively. One hundred and seventy-

four patients (49.2%) were male and 38/354 (10.7%) were smokers. There were

147/354 (41.5%) patients with BX, 87/354 (24.6%) with CF, 53/354 (15.0%) with

COPD, 32/354 (9.0%) with asthma, 19/354 (5.4%) with allergic bronchopulmonary

aspergillosis (ABPA), 17/354 (4.8%) with interstitial lung disease (ILD) and 7/354

(2.0%) with other underlying respiratory conditions such as pleural thickening or

sarcoidosis. Patients with no other respiratory disease or predisposition to NTM

infections accounted for 3.4% (12/354) of the cohort. During the study period, 55/354

(15.5%) patients were on antibiotic treatment regimes. For 20 patients (5.6%) clinical

data were unavailable.

Species distribution

A total of 996 isolates from 354 patients were successfully sequenced and the nine

MAC species identified are detailed in Table 1. The three predominant species

amongst the sequenced isolates were *M. avium (M. avium* subsp. *avium* and *M. avium*

subsp. *hominissuis)*, *M. chimaera* and *M. intracellulare.* Together these accounted

for 926/996 (93.0%) of the MAC isolates sequenced. Most patients were infected

with only a single species during the collection period. However, 45 of the 354

patients (12.7%) were infected with two or more species (Fig 1A). In this group of

patients, most of the isolates collected were typically from a single species, with other

species observed more infrequently (Fig 1B). Subsequent analyses in this study will

focus on the three predominant species in the dataset: *M. intracellulare, M. avium (M.*

avium subsp. *avium* and *M. avium* subsp. *hominissuis)*, and *M. chimaera*.

M. intracellulare

A total of 162 genomes from 37 patients were identified as *M. intracellulare* (Fig 2A).

Eleven of the patients had CF, seventeen had BX, with the remaining seven having

other lung conditions (COPD n = 3; ILD n = 3; asthma n = 1; congenital pulmonary

airway malformation [CPAM] n = 1) and disease metadata were missing for two

patients. Genomic clustering with fastBAPs identified nine lineages with three of

these having more than ten genomes (Fig 2A). Following remapping to local

references for the three largest fastBAPS lineages, three putative transmission

clusters were identified with the largest, Mi_FB3_1, composed of 16 patients (Fig 2B;

Table B in S1 Data). Of these 16 patients, eight had BX, seven CF and one ILD. The

range of the number of isolates collected per patient was between one and 32. Four

of the sixteen patients were also infected with other species or lineages during the

sampling period with Mi_FB3_1 only being detected in 1/22 isolates collected for

patient 218 (Fig 2B). During the time period that the sequenced isolates were

collected, four of the patients (85, 95, 97 and 99), were being treated with antibiotics

and three of the four patients were treated successfully. No epidemiological links

were identified between patients in the year prior to isolate collection. Comparison

with 77 previously published *M. intracellulare* isolates showed that the most closely

related contextual isolate was collected in the UK in 2015/2016 [32] and formed part

of a clade containing isolates from the Mi_FB3_1 cluster (Fig 2C). The remainder of

the RBH isolates were evenly distributed through the global phylogenetic tree.

M. avium

A total of 405 sequenced isolates collected from 176 patients were identified as *M.*

avium. Of the patients infected with *M. avium*, 44 had CF and 81 BX. Sequence data

for all *M. avium* isolates was mapped to a single reference (*M. avium* subsp. *avium*

104; NC008595.1) and a phylogenetic tree constructed with a previously published

M. avium subsp. *paratuberculosis* isolate (DRR263663) chosen as an outgroup (Fig B

in S1 Data). The structure of this phylogeny showed that there were two major clades

which corresponded to the two subspecies *M. avium* subsp. *avium* (n = 207; MAA)

and *M. avium* subsp. *hominissuis* (n = 198; MAH). Isolates for each of the two

subspecies were next analysed separately. A small number of patients were infected

with both subspecies (n = 6). No examples of the other two *M. avium* subspecies,

paratuberculosis and *silvaticum*, were identified in this study.

M. avium avium (MAA)

Of the 76 patients infected with MAA, 15 had CF, 39 had BX and 16 had other lung

conditions (COPD n = 10; ILD n = 3; ABPA n = 3; asthma n = 6) whilst three patients,

including one smoker, had no pre-existing respiratory disease (metadata were

unavailable for three patients; Fig 3A). Clustering of the 207 MAA genomes identified

17 fastBAPS lineages (Fig 3A). Remapping of the four largest fastBAPS lineages

allowed the identification of seven putative transmission clusters comprising between

two and ten patients (Table C in S1 Data) with the largest cluster of ten isolates

comprised of patients with CF (n = 2), BX (n = 6) and asthma or COPD (n =2; Fig 3B).

A total of 21 fastBAPS lineages were defined in the global phylogeny (Fig 3C).

Examination of the distribution of pairwise SNP distances for each fastBAPS lineage

containing at least ten genomes revealed that there were two lineages containing

RBH isolates with lower median pairwise SNP distances (FB10 and FB15; Fig 3C and

Fig CB in S1 Data). The 23 genomes, including two RBH genomes, in FB10 were

collected in the UK between 2013 and 2016, with most coming from the National

Mycobacterial Reference Service. The latter characterises mycobacterial cultures

from across the Midlands and North of England (Fig 5A) (37). If the SNP threshold

used to calculate putative transmission clusters circulating in the RBH was applied,

then one isolate from the RBH (40-1) formed part of a cluster comprised of isolates

from Quan *et al.* (37). The majority (35/46) of the isolates forming FB15 were collected

in the USA with most from a study investigating *M. avium* in the community and

household water in Philadelphia (Fig 5B) (33). The pairwise distances between two

of the RBH isolates and other UK isolates and isolates from the USA in FB15 were

within the threshold used to define transmission, suggesting potential cross-Atlantic

transmission (Fig DA in S1 Data).

M. avium hominissuis (MAH)

A total of 198 genomes from 106 patients were characterised as MAH (Fig 4A). Thirty-

three patients had CF, 43 BX and 21 had other lung conditions (COPD n = 14; ILD n

= 1; ABPA n = 5; sarcoidosis n = 1; asthma n = 11). Four patients had no pre-existing

respiratory disease. Disease metadata were unavailable for the remaining five

patients. Genomic clustering identified 17 lineages and seven putative transmission

clusters containing between two and 16 patients (Table D in S1 Data). The largest

cluster of 16 isolates is shown in Figure 4B and comprised patients with CF (n = 4),

BX (n = 7), COPD (n = 3) and a single patient with no pre-existing lung condition

(metadata were unavailable for one patient). Two pairs of patients in each of the

clusters, MAH_FB8_1 and MAH_FB14_9, were found to have epidemiological links.

Of the 20 defined fastBAPS lineages in the global collection, FB6 and FB11 had lower

median pairwise SNP distances and contained RBH isolates (Fig 4C and Fig CC in

S1 Data). Both lineages were composed completely or near-completely of isolates

collected in the UK (Fig 5C and Fig 5D). The star-like structure of the FB6 phylogeny

is suggestive of a point source outbreak and applying a transmission SNP threshold

of 16 SNPs showed that 41/45 of the isolates in FB6 would have formed a

transmission cluster that included both isolates from this study and isolates from

other UK studies (Fig DB in S1 Data) (35,37). Two small transmission clusters,

containing RBH and other UK isolates, were also identified in FB11.

M. chimaera

There were 359 sequenced isolates collected from 155 patients identified as *M.*

chimaera; 37 of the patients had CF, 60 had BX whilst 50 patients had other lung

conditions (COPD n = 24; ILD n =10; ABPA n = 11; pleural thickening with enfolded

lung n = 1; lung non-mucinous adenocarcinoma n = 1; Wegener's granulomatosis n

= 1; *M. tuberculosis* in lymph nodes during same endoscopy procedure n = 1; primary

ciliary dyskinesia n = 1; asthma n = 17). There were five patients with no pre-existing

respiratory disease and metadata were unavailable for a further nine patients. A single

predominant lineage, Mc_FB1, corresponding to the previously characterised Group

1 accounted for 332/359 (92.5%) of the sequenced isolates with the majority of the

remaining isolates (25/359; 7.0%) forming a second main lineage Mc_FB2

corresponding to Group 2 (Fig 6A). Thirteen putative transmission clusters containing

two to 106 patients were identified (Table E in S1 Data). Twelve potential

epidemiological links between 15 different patients were found in transmission cluster

Mc_FB3_1, the largest transmission cluster of 106 patients (Fig 6B; Table F in S1

Data). Of the patients in this cluster 43 had BX, 24 CF, 13 COPD, 14 asthma, seven

ILD, two ABPA, one pleural thickening with enfolded lung, one lung non-mucinous

adenocarcinoma and one primary ciliary dyskinesia. Three patients had no pre-

existing lung condition and disease status was missing for five patients. Fifteen

patients underwent antibiotic treatment during the study period.

The global phylogenetic tree containing 155 isolates from RBH and 671 previously

published isolates was topologically similar to the tree built using only the isolates

from RBH with a single major clade with low genetic diversity present (FB6; Fig 6C).

Isolates from the two clusters with more than ten representatives (FB5 and FB6) were

remapped to local references. Recombination was removed and new phylogenetic

trees constructed (Fig 7A [FB5] and Fig 7B [FB6]). Most isolates in FB5 were collected

from patients with respiratory conditions or else patients with infections following

cardiac surgeries. There was, however, a distinct sub-clade rooting within this

diversity containing only isolates from HCUs or hospital water supplies (Fig 7B).

Within FB6 a more deeply rooting diverse clade contained mainly human isolates and

the larger shallower clade rooting within this contained most of the HCU isolates

interspersed with human isolates (Fig 7B and Fig 7C). Due to the large number of

isolates assigned to FB6 (n = 765), further genomic lineage assignment was

performed using fastBAPS to identify five sub-lineages within FB6 (Fig 7B and Fig

7C). New mapping was performed for the three lineages with more than ten isolates

(FB6_FB1, FB6_FB2 and FB6_FB4; Fig 8A-8C;). Two of these lineages, FB6_FB2

and FB6_FB4, were completely or nearly completely composed of patient isolates

(Fig 8B and Fig 8C). Most of the isolates collected from HCUs or water supplies

made up the bulk of FB6_FB1, though human isolates were distributed throughout

the tree (Fig 8A). Putative transmission clusters were calculated for all five fastBAPS

lineages described above used a pairwise SNP threshold of 30 SNPs (Table G in S1

Data). Transmission clusters containing RBH isolates were found in each of the

lineages with the largest, found in FB6_FB1, comprising 258 HCU isolates, 230

patient isolates and a single isolate from a water supply (Table G in S1 Data).

Discussion

The aims of this study were to characterise the population structure of MAC and

identify potential transmission between CF and non-CF patients. We used a dataset

of 996 sequenced MAC isolates collected in a London hospital. This is, to date, the

largest sequenced MAC isolate collection analysed from a single location. We

showed that polymicrobial infection with MAC is not uncommon. The large,

longitudinal dataset enabled us to identify putative transmission clusters for all four

species/sub-species we considered. Most of these transmission clusters contained

both patients with CF and non-CF patients, showing that transmission of MAC is

occurring despite the presence of hospital-based control measures focussing on

patients with CF. The lack of clear epidemiological links suggests that the majority

of transmission is not due to direct patient-to-patient transmission but rather through

intermediates such as a local environmental vector or asymptomatic carriage in the

wider population. Comparison of the isolates collected as part of this study with

published isolates identified a small number of lineages likely circulating in the UK.

With the exception of the major HCU-associated lineage in *M. chimaera*, the

comparison did not identify globally circulating lineages like those observed in *M.*

abscessus. Surprisingly, given the previous description of the *M. chimaera* HCU

clade as representing an environmental point source outbreak (12), we provide

evidence that the lineage which was responsible for the HCU-vectored *M. chimaera*

outbreak was derived from an existing lineage which was already circulating amongst

patients with pre-existing lung conditions, and that this introduction into HCUs

happened on at least two separate occasions (only one of which led to the global

outbreak). This indicates that, while infection and distribution of HCUs was clearly

responsible for the global transmission of one sub-lineage, they were not the primary

source of this lineage, which was derived from a lineage that was already circulating

in the human population prior to the HCU outbreak. Further, there is evidence of

onward transmission into non-cardiac patients of the HCU-sub-lineage, indicating

that local establishment and transmission can still occur independent of direct

infection by HCUs.

During the isolate sampling period we identified 45 patients infected with more than

one species or lineage. This suggests that many of the patients had polymicrobial

infections and that certain lineages were preferentially sampled and cultured at

different times. This has been observed previously in other longitudinal samples of

patients with MAC lung disease (38). These observations suggest that single colony

picks during culturing potentially may be underrepresenting the underlying diversity

of MAC species in patients with MAC lung disease. Therefore, to better understand

the ecology and transmission of MAC species in the lung, a deep sequencing

approach in which colony sweeps rather than colony picks are utilised should be

considered for future studies.

Previous studies have used SNP thresholds of 15-25 SNPs to identify putative

transmission clusters in NTM species (13,18,33). Rather than using a previously

applied or arbitrary threshold, we used a method that had previously been used to

define SNP thresholds in *Staphylococcus aureus* (55). This allowed us to calculate a

SNP threshold for each species using the longitudinal isolates collected by the RBH.

The thresholds calculated for *M. intracellulare* and MAH of 16 SNPs were similar to

those previously applied. Whilst we obtained higher thresholds of 30 SNPs and 58

SNPs for *M. chimaera* and MAA respectively, this did not result in an inflated number

of transmission clusters, as applying a threshold of 16 SNPs to the MAA dataset

would have resulted in only two fewer clusters. These larger values were

predominantly due to high levels of within-host diversity observed amongst patient

isolates in single clusters in both MAA and *M. chimaera*. For instance, in MAA_FB14

isolates from a single patient collected a day apart were as much as 101 SNPs

different. This highlighted the likelihood of polymicrobial infections being common

amongst the patients we included in the study.

Using the SNP thresholds calculated for each species, we were able to identify

putative transmission clusters amongst all four of the MAC species/subspecies we

considered. Broadly, two different patterns of infection were observed: amongst *M.*

intracellulare and the two *M. avium* subspecies, our results suggested that there have

been multiple independent introductions into the human population followed by

limited transmission. Our analysis of *M. chimaera*, however, identified a single large

transmission cluster was responsible for infecting 106/155 (68.4%) of our patients

infected with this species. Most of these transmission clusters contained both CF

and non-CF patients and a small number also contained patients with no pre-existing

lung conditions.

Using our criteria, we were unable to identify potential epidemiological links for most

patients included in the transmission clusters. The exception to this was the largest

M. chimaera transmission cluster where we found 12 potential epidemiological links

up to a year before sampling began. Interestingly, four patients were part of more

than one link, with patient 218 overlapping with other patients in this transmission

cluster on the same wards six times over a nine-month period. The tight infection

control surrounding patients with CF, which prioritises preventing cross-infection

through hygiene and segregation, means that they are unlikely to have interacted with

patients with other lung conditions whilst in hospital. Outpatient clinics are organised

so that patients are seen individually and, during inpatient care, CF patients are given

individual rooms with en-suite facilities. This implies that transmission is likely

occurring *via* other pathways, such as through environmental intermediates or

through a reservoir of healthy, asymptomatic carriers in the wider population. This

observation is not unique and for some time, there has been considerable debate

whether NTM transmission between patients is occurring, even when transmission is

strongly supported by genome-based analysis (13,18,58). The near complete

absence of epidemiological links between patients in transmission clusters as well as

the ubiquitous presence of NTM species in the environment, especially water

supplies, has led some researchers to suggest that the dissemination of NTM

lineages at a national level is associated with exposure to contaminated water

supplies (18). Whilst there is certainly strong evidence for the same lineages being

isolated from water supplies and patients in the same location [28], the absence of a

single national water supply even in a comparatively small country like the UK would

suggest that closely related isolates collected from different geographical locations

are unlikely to be due to a single contaminated water supply. It is however possible

that transmission networks may include local water supplies as intermediates. The

alternative hypothesis that NTM populations are being maintained in apparently

healthy individuals with no symptoms of NTM lung disease is equally worthy of

consideration. This would explain the presence of local transmission clusters in the

absence of direct epidemiological links as well as the presence of phylogeographical

structure in NTM trees. To better address how NTM species are being transmitted,

future studies should focus on attempting to collect isolates from the general

population, perhaps focussing on smokers where there is some evidence that they

may provide a better reservoir for NTM species and other opportunistic pathogens

(19).

The inclusion of published genomes alongside the RBH isolates allowed us to use

our defined pairwise SNP thresholds to identify putative MAC lineages circulating in

the UK and globally. Apart from the *M. chimaera* lineages that were known to be

associated with HCUs, we were unable to identify large globally circulating lineages

like those observed in *M. abscessus*. This potentially suggests different evolutionary

dynamics amongst the MAC species or, in the case of *M. intracellulare*, may simply

reflect a lack of comprehensive sampling. We were only able to identify a single

lineage containing RBH isolates amongst the two *M. avium* subspecies that included

isolates from outside the UK. This cluster comprised the majority of isolates in FB15

(Figure 5B). Given that most available *M. avium* genomes have been collected in the

UK or USA, a more comprehensive global sampling strategy could potentially reveal

the existence of additional globally circulating clones.

A different picture emerged when we calculated global transmission clusters for *M.*

chimaera using a pairwise SNP threshold of 30 SNPs (Supplementary Table 7). Here

we found that most clusters either consisted of isolates from across Europe or else

also included isolates from other parts of the world such as Australia. Notably, we

identified a single large transmission cluster containing 489 isolates from 12 countries

that included most of the HCU-associated isolates. Previous work investigating the

global population structure of *M. chimaera* has suggested that the majority of *M.*

chimaera transmission globally was associated with point source contamination of

HCUs during manufacturing which then led to onward transmission to patients

undergoing cardiac surgery (12). In our study we have assembled the largest *M.*

chimaera dataset analysed to date, including isolates collected from HCUs and

cardiac patients as well as from patients with lung conditions such as CF and BX.

This has enabled us to investigate the global population structure of *M. chimaera* in

more detail than has previously been possible (12,59). Strikingly, we discovered clear

evidence for distinct lineages within the global phylogeny that were almost exclusively

associated with patient isolates. In addition, most of the HCU-associated isolates

were clustered together in a single lineage that was derived from the lineages

containing only human isolates (Figure 6B). This was also true of a second, smaller,

lineage that contained only HCU and environmental isolates. The results suggest that

the predominant HCU-associated lineage is descended from a *M. chimaera*

population already circulating amongst patients with respiratory diseases such as CF,

and that a similar derivation has happened at least once more. Unfortunately, due to

the absence of even a moderate temporal signal (data not shown), we were unable

to place any estimates of when these lineages first emerged.

Potential limitations of this study are the lack of environmental samples as well as the

distinct bias with respect to country of isolation in the contextual dataset. Given, the

lack of direct patient to patient contact and epidemiological links, the inclusion of

samples collected from the wards admitting patients and hospital water supplies

would potentially have revealed additional vectors of transmission. Assembling

useful contextual datasets is reliant on what is available in the public domain and the

geographical bias towards the USA and UK in the contextual datasets we used is not

confined to this study. For many pathogens, most studies have focussed on resource

richer settings. However, given the increasing availability of genome sequencing, it

is likely that NTM datasets from other settings will be available to include in future

analyses.

In conclusion, using a large longitudinal sample of MAC isolates collected within a

single hospital as well as previously published global contextual isolates, we were

able to identify polymicrobial infections by different MAC species and lineages in

multiple patients as well as identify transmission clusters representing lineages

circulating within the hospital, at a national level and, less commonly, globally. We

show that the origin of the major HCU-associated *M. chimaera* lineage is likely a

previously circulating lineage associated with patients with respiratory diseases. To

better understand the transmission dynamics and to prevent continuing circulation of

MAC and other NTM species, future studies should include sampling of

environmental reservoirs and potential asymptomatic carriers.

Data availability

Raw sequencing reads were deposited at the European Nucleotide Archive under

project PRJEB21813; all accessions used in this project are listed in Supplementary

File 1.

Code availability

The R code used to perform data analyses in this study is available in GitHub

(https://github.com/avantonder/MAC).

Funding

This project was supported by the Asmarley Trust, the Wellcome Trust and the NIHR

Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield

NHS Foundation Trust, Imperial College London. Huw Ellis' CRF was funded by a

grant from the Welton Foundation.

Conflicts of interest

JP is a paid consultant to NextGen Diagnostics LLc.

References

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416.

2. Chan ED, Bai X, Kartalija M, Orme IM, Ordway DJ. Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am J Respir Cell Mol Biol. 2010 Oct;43(4):387–93.

3. Iseman MD, Marras TK. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2008 Nov 15;178(10):999–1000.

4. Donohue MJ, Wymer L. Increasing Prevalence Rate of Nontuberculous Mycobacteria Infections in Five States, 2008-2013. Ann Am Thorac Soc. 2016 Dec;13(12):2143–50.

5. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health. 2010 Oct 15;10:612.

6. Philley JV, Griffith DE. Treatment of slowly growing mycobacteria. Clin Chest Med. 2015 Mar;36(1):79–90.

7. Adjemian J, Olivier KN, Prevots DR. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014. Ann Am Thorac Soc. 2018 Jul;15(7):817–26.

8. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013 Dec;42(6):1604–13.

9. Olivier KN, Weber DJ, Wallace RJ, Faiz AR, Lee J-H, Zhang Y, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003 Mar 15;167(6):828–34.

10. Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, et al. Prosthetic valve endocarditis and bloodstream infection due to Mycobacterium chimaera. J Clin Microbiol. 2013 Jun;51(6):1769–73.

11. Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, et al. Prolonged Outbreak of Mycobacterium chimaera Infection After Open-Chest Heart Surgery. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015 Jul 1;61(1):67–75.

12. van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafrańska A, et al. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. Lancet Infect Dis. 2017 Oct;17(10):1033–41.

13. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome
sequencing to identify transmission of Mycobacterium abscessus between patients with
cystic fibrosis: a retrospective cohort study. Lancet Lond Engl. 2013 May
4;381(9877):1551–60.

14. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al.
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous
mycobacterium. Science. 2016 Nov 11;354(6313):751–7.

15. Everall I, Nogueira CL, Bryant JM, Sánchez-Busó L, Chimara E, Duarte R da S, et al.
Genomic epidemiology of a national outbreak of post-surgical Mycobacterium abscessus
wound infections in Brazil. Microb Genomics. 2017 May;3(5):e000111.

16. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, et al. Respiratory
outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and
cystic fibrosis center. Am J Respir Crit Care Med. 2012 Jan 15;185(2):231–2.

17. Davidson RM, Hasan NA, Epperson LE, Benoit JB, Kammlade SM, Levin AR, et al.
Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care
Centers. Ann Am Thorac Soc. 2021 Dec;18(12):1960–9.

18. Lipworth S, Hough N, Weston N, Muller-Pebody B, Phin N, Myers R, et al. Epidemiology
of Mycobacterium abscessus in England: an observational study. Lancet Microbe. 2021
Oct;2(10):e498–507.

19. Ruis C, Bryant JM, Bell SC, Thomson R, Davidson RM, Hasan NA, et al. Dissemination of
Mycobacterium abscessus via global transmission networks. Nat Microbiol. 2021
Oct;6(10):1279–88.

20. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence
Data [Internet]. [cited 2021 Dec 14]. Available from:
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/

21. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using
exact alignments. Genome Biol. 2014 Mar 3;15(3):R46.

22. Lu J, Breitwieser FP, Thielen P, Salzberg SL. Bracken: estimating species abundance in
metagenomics data. PeerJ Comput Sci. 2017 Jan 2;3:e104.

23. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
data. Bioinforma Oxf Engl. 2014 Aug 1;30(15):2114–20.

24. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
Bioinforma Oxf Engl. 2009 Jul 15;25(14):1754–60.

25. Harris SR, Feil EJ, Holden MTG, Quail MA, Nickerson EK, Chantratita N, et al. Evolution of
MRSA during hospital transmission and intercontinental spread. Science. 2010 Jan
22;327(5964):469–74.

26. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: rapid
efficient extraction of SNPs from multi-FASTA alignments. Microb Genomics. 2016
Apr;2(4):e000056.

27. Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective
stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol.
2015 Jan;32(1):268–74.

28. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid
phylogenetic analysis of large samples of recombinant bacterial whole genome
sequences using Gubbins. Nucleic Acids Res. 2015 Feb 18;43(3):e15.

29. Tonkin-Hill G. pairsnp [Internet]. 2021 [cited 2021 Dec 14]. Available from:
https://github.com/gtonkinhill/pairsnp

30. Caverly LJ, Spilker T, LiPuma JJ. Complete Genome Sequence of Mycobacterium
abscessus subsp. bolletii. Genome Announc. 2016 Jun 9;4(3):e00543-16.

31. Hasan NA, Davidson RM, Epperson LE, Kammlade SM, Rodger RR, Levin AR, et al.
Population Genomics of Nontuberculous Mycobacteria Recovered from United States
Cystic Fibrosis Patients [Internet]. 2019 Jun [cited 2021 Dec 14] p. 663559. Available
from: https://www.biorxiv.org/content/10.1101/663559v1

32. Bryant JM, Thibault VC, Smith DGE, McLuckie J, Heron I, Sevilla IA, et al. Phylogenomic
exploration of the relationships between strains of Mycobacterium avium subspecies
paratuberculosis. BMC Genomics. 2016 Jan 26;17:79.

33. Lande L, Alexander DC, Wallace RJ, Kwait R, Iakhiaeva E, Williams M, et al.
Mycobacterium avium in Community and Household Water, Suburban Philadelphia,
Pennsylvania, USA, 2010-2012. Emerg Infect Dis. 2019 Mar;25(3):473–81.

34. Yoon J-K, Kim TS, Kim J-I, Yim J-J. Whole genome sequencing of Nontuberculous
Mycobacterium (NTM) isolates from sputum specimens of co-habiting patients with
NTM pulmonary disease and NTM isolates from their environment. BMC Genomics.
2020 Apr 23;21(1):322.

35. Votintseva AA, Pankhurst LJ, Anson LW, Morgan MR, Gascoyne-Binzi D, Walker TM, et
al. Mycobacterial DNA extraction for whole-genome sequencing from early positive
liquid (MGIT) cultures. J Clin Microbiol. 2015 Apr;53(4):1137–43.

36. Pfeiffer W, Braun J, Burchell J, Witte CL, Rideout BA. Whole-genome analysis of
mycobacteria from birds at the San Diego Zoo. PloS One. 2017;12(3):e0173464.

37. Quan TP, Bawa Z, Foster D, Walker T, Del Ojo Elias C, Rathod P, et al. Evaluation of
Whole-Genome Sequencing for Mycobacterial Species Identification and Drug
Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of
Performance against Line Probe Assays and Phenotyping. J Clin Microbiol. 2018
Feb;56(2):e01480-17.

38. Operario DJ, Pholwat S, Koeppel AF, Prorock A, Bao Y, Sol-Church K, et al.
Mycobacterium avium Complex Diversity within Lung Disease, as Revealed by Whole-
Genome Sequencing. Am J Respir Crit Care Med. 2019 Aug 1;200(3):393–6.

39. Rivas AE, Hollinger C, Oehler DA, Robbe-Austerman S, Paré JA. DIAGNOSIS AND
MANAGEMENT OF MYCOBACTERIOSIS IN A COLONY OF LITTLE PENGUINS (EUDYPTULA
MINOR). J Zoo Wildl Med Off Publ Am Assoc Zoo Vet. 2019 Jun 13;50(2):427–36.

40. Chand M, Lamagni T, Kranzer K, Hedge J, Moore G, Parks S, et al. Insidious Risk of Severe
Mycobacterium chimaera Infection in Cardiac Surgery Patients. Clin Infect Dis Off Publ
Infect Dis Soc Am. 2017 Feb 1;64(3):335–42.

41. Pankhurst LJ, Del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, et al. Rapid,
comprehensive, and affordable mycobacterial diagnosis with whole-genome
sequencing: a prospective study. Lancet Respir Med. 2016 Jan;4(1):49–58.

42. Epperson LE, Timke M, Hasan NA, Godo P, Durbin D, Helstrom NK, et al. Evaluation of a
Novel MALDI Biotyper Algorithm to Distinguish Mycobacterium intracellulare From
Mycobacterium chimaera. Front Microbiol. 2018;9:3140.

43. Acosta F, Pérez-Lago L, Ruiz Serrano MJ, Marín M, Kohl TA, Lozano N, et al. Fast update
of undetected Mycobacterium chimaera infections to reveal unsuspected cases. J Hosp
Infect. 2018 Dec;100(4):451–5.

44. Ghodousi A, Borroni E, Peracchi M, Palù G, Fallico L, Rassu M, et al. Genomic analysis of
cardiac surgery-associated Mycobacterium chimaera infections in Italy. PloS One.
2020;15(9):e0239273.

45. Mac Aogáin M, Roycroft E, Raftery P, Mok S, Fitzgibbon M, Rogers TR. Draft Genome
Sequences of Three Mycobacterium chimaera Respiratory Isolates. Genome Announc.
2015 Dec 3;3(6):e01409-15.

46. Perkins KM, Lawsin A, Hasan NA, Strong M, Halpin AL, Rodger RR, et al. Notes from the
Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in
Cardiac Surgery - United States. MMWR Morb Mortal Wkly Rep. 2016 Oct
14;65(40):1117–8.

47. Svensson E, Jensen ET, Rasmussen EM, Folkvardsen DB, Norman A, Lillebaek T.
Mycobacterium chimaera in Heater-Cooler Units in Denmark Related to Isolates from
the United States and United Kingdom. Emerg Infect Dis. 2017 Mar;23(3):507–9.

48. Williamson D, Howden B, Stinear T. Mycobacterium chimaera Spread from Heating and
Cooling Units in Heart Surgery. N Engl J Med. 2017 Feb 9;376(6):600–2.

49. Zhang X, Lin J, Feng Y, Wang X, McNally A, Zong Z. Identification of Mycobacterium
chimaera in heater-cooler units in China. Sci Rep. 2018 May 18;8(1):7843.

50. Page AJ, De Silva N, Hunt M, Quail MA, Parkhill J, Harris SR, et al. Robust high-
throughput prokaryote de novo assembly and improvement pipeline for Illumina data.
Microb Genomics. 2016 Aug;2(8):e000083.

51. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a
new genome assembly algorithm and its applications to single-cell sequencing. J Comput
Biol J Comput Mol Cell Biol. 2012 May;19(5):455–77.

52. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. Scaffolding pre-assembled
contigs using SSPACE. Bioinforma Oxf Engl. 2011 Feb 15;27(4):578–9.

53. Boetzer M, Pirovano W. Toward almost closed genomes with GapFiller. Genome Biol.
2012 Jun 25;13(6):R56.

54. Tonkin-Hill G, Lees JA, Bentley SD, Frost SDW, Corander J. Fast hierarchical Bayesian
analysis of population structure. Nucleic Acids Res. 2019 Jun 20;47(11):5539–49.

55. Coll F, Raven KE, Knight GM, Blane B, Harrison EM, Leek D, et al. Definition of a genetic
relatedness cutoff to exclude recent transmission of meticillin-resistant Staphylococcus
aureus: a genomic epidemiology analysis. Lancet Microbe. 2020 Dec;1(8):e328–35.

56. R Core Team (2020). — European Environment Agency [Internet]. [cited 2021 Dec 14].
Available from: https://www.eea.europa.eu/data-and-maps/indicators/oxygen-
consuming-substances-in-rivers/r-development-core-team-2006

57. Csardi G, Nepusz T. The Igraph Software Package for Complex Network Research.
InterJournal. 2005 Nov 30;Complex Systems:1695.

58. Bronson RA, Gupta C, Manson AL, Nguyen JA, Bahadirli-Talbott A, Parrish NM, et al.
Global phylogenomic analyses of Mycobacterium abscessus provide context for non
cystic fibrosis infections and the evolution of antibiotic resistance. Nat Commun. 2021
Aug 26;12(1):5145.

59. Schreiber PW, Kohl TA, Kuster SP, Niemann S, Sax H. The global outbreak of
Mycobacterium chimaera infections in cardiac surgery-a systematic review of whole-
genome sequencing studies and joint analysis. Clin Microbiol Infect Off Publ Eur Soc Clin
Microbiol Infect Dis. 2021 Nov;27(11):1613–20.

Tables and Figures

723   Table 1. *Mycobacterium avium* complex species identified in the Royal Brompton

724   Hospital Collection.

Species	Number of genomes
M. avium	405
M. chimaera	359
M. intracellulare	162
Mycobacterium sp. MOTT36Y	39
M. paraintracellulare	15
M. yongonense	10
M. marseillense	4
M. colombiense	1
Mycobacterium sp. QIA-37	1

Fig 1. Patients infected by more than one *Mycobacterium avium* Complex (MAC)

species. A) Histogram showing the number of *Mycobacterium avium* complex

species identified in each patient; B) Timeline of patients infected by more than one

Mycobacterium avium Complex (MAC) species. Each point represents an isolate and

is coloured according to the species identified. Isolates from the species in a patient

are linked together. Patients with one isolate or multiple isolates from a single species

were excluded.

Fig 2: Population structure and transmission of *Mycobacterium intracellulare*.

A) Midpoint-rooted maximum likelihood phylogenetic tree for *Mycobacterium intracellulare* isolates collected at the Royal Brompton Hospital (n = 162). The taxa are clustered according to their sequence similarities. The lengths of the branches are scaled in nucleotide substitutions per site. The disease status of the patients (that isolates were collected from) for cystic fibrosis and non-cystic fibrosis bronchiectasis are represented by red bars for Yes and white bars for No with missing patient data shown by gray bars. Scale bars are shown in SNPs per site.; B) *Mycobacterium intracellulare* Mi_FB3_1 transmission cluster. Each node represents an isolate or isolates identical (0 SNPs) to each other and the size of the node is proportional to the number of identical isolates. Nodes are coloured and labelled by patient number. The outer ring of each node is coloured according to the disease status of the patient (cystic fibrosis = black, non-cystic fibrosis bronchiectasis = red, grey = other lung condition). The edges represent the pairwise SNP distance between the isolate(s); C) Midpoint-rooted maximum likelihood phylogenetic tree for global *Mycobacterium intracellulare* isolates (n = 114). The taxa are clustered according to their sequence similarities. The lengths of the branches are scaled in nucleotide substitutions per

 site. fastBAPS lineage, source of isolate, country of collection and study are shown

758 as datastrips to the right of the phylogenies. Isolates from the Royal Brompton

759 Hospital are highlighted in red. Scale bars are shown in SNPs per site.

Fig 3. Population structure and transmission of *Mycobacterium avium* subsp.

avium. A) Midpoint-rooted maximum likelihood phylogenetic tree for *Mycobacterium*

avium subsp. *avium* isolates collected at the Royal Brompton Hospital (n = 207). The

taxa are clustered according to their sequence similarities. The lengths of the

branches are scaled in nucleotide substitutions per site. The disease status of the

patients (that isolates were collected from) for cystic fibrosis and non-cystic fibrosis

bronchiectasis are represented by red bars for Yes and white bars for No with missing

patient data shown by gray bars. Scale bars are shown in SNPs per site; B)

Mycobacterium avium subsp. *avium* MAA_FB5_1 transmission cluster. Each node

represents an isolate or isolates identical (0 SNPs) to each other and the size of the

node is proportional to the number of identical isolates. Nodes are coloured and

labelled by patient number. The outer ring of each node is coloured according to the

disease status of the patient (cystic fibrosis = black, non-cystic fibrosis

bronchiectasis = red, grey = other lung condition). The edges represent the pairwise

SNP distance between the isolate(s); C) Midpoint-rooted maximum likelihood

phylogenetic tree for global *Mycobacterium avium* subsp. *avium* isolates (n = 344).

The taxa are clustered according to their sequence similarities. The lengths of the

branches are scaled in nucleotide substitutions per site. fastBAPS lineage, source of

isolate, country of collection and study are shown as datastrips to the right of the

phylogenies. Isolates from the Royal Brompton Hospital are highlighted in red. Scale

bars are shown in SNPs per site.

788 **Fig 4. Population structure and transmission of *Mycobacterium avium* subsp.**

789 ***hominissuis*.** A) Midpoint-rooted maximum likelihood phylogenetic tree for

790 *Mycobacterium avium* subsp. *Hominissuis* isolates collected at the Royal Brompton

791 Hospital (n = 198). The taxa are clustered according to their sequence similarities.

792 The lengths of the branches are scaled in nucleotide substitutions per site. The

793 disease status of the patients (that isolates were collected from) for cystic fibrosis

794 and non-cystic fibrosis bronchiectasis are represented by red bars for Yes and white

795 bars for No with missing patient data shown by gray bars. Scale bars are shown in

796 SNPs per site; B) *Mycobacterium avium* subsp. *hominissuis* MAH_FB8_1

797 transmission cluster. Each node represents an isolate or isolates identical (0 SNPs)

798 to each other and the size of the node is proportional to the number of identical

799 isolates. Nodes are coloured and labelled by patient number. The outer ring of each

800 node is coloured according to the disease status of the patient (cystic fibrosis = black,

801 non-cystic fibrosis bronchiectasis = red, grey = other lung condition). The edges

802 represent the pairwise SNP distance between the isolate(s); C) Midpoint-rooted

803 maximum likelihood phylogenetic tree for global *Mycobacterium avium* subsp.

804 *hominissuis* isolates (n = 236). The taxa are clustered according to their sequence

805 similarities. The lengths of the branches are scaled in nucleotide substitutions per

806 site. fastBAPS lineage, source of isolate, country of collection and study are shown

807 as datastrips to the right of the phylogenies. Isolates from the Royal Brompton

808 Hospital are highlighted in red. Scale bars are shown in SNPs per site.

Fig 5: *Mycobacterium avium* global fastBAPS phylogenies. Midpoint-rooted

maximum likelihood phylogenetic trees for A) *Mycobacterium avium* subsp. *avium*

FB10; B) *Mycobacterium avium* subsp. *avium* FB15; C) *Mycobacterium avium* subsp.

hominissuis FB6 and D) *Mycobacterium avium* subsp. *hominissuis* FB11. The taxa are

clustered according to their sequence similarities. The lengths of the branches are

scaled in nucleotide substitutions per site. The source of isolate, country of collection

and study are shown as datastrips to the right of the phylogenies. Isolates from the

Royal Brompton Hospital are highlighted in red. Branch lengths are shown in SNPs per site.

Fig 6. Population structure and transmission of *Mycobacterium chimaera.* A) Midpoint-rooted maximum likelihood phylogenetic tree for *Mycobacterium chimaera* isolates collected at the Royal Brompton Hospital (n = 359). The taxa are clustered according to their sequence similarities. The lengths of the branches are scaled in nucleotide substitutions per site. The disease status of the patients (that isolates were collected from) for cystic fibrosis and non-cystic fibrosis bronchiectasis are represented by red bars for Yes and white bars for No with missing patient data shown by gray bars. Scale bars are shown in SNPs per site; B) *Mycobacterium chimaera* Mc_FB3_1 transmission cluster. Each node represents an isolate or isolates identical (0 SNPs) to each other and the size of the node is proportional to the number of identical isolates. Nodes are coloured according to patient disease status and labelled by patient number. The edges represent the pairwise SNP distance between the isolate(s); C) Rooted maximum likelihood phylogenetic tree for global

Mycobacterium chimaera isolates (n = 826). The taxa are clustered according to their sequence similarities. The lengths of the branches are scaled in nucleotide substitutions per site. fastBAPS lineage, source of isolate, country of collection and study are shown as datastrips to the right of the phylogenies. Isolates from the Royal Brompton Hospital are highlighted in red. Scale bars are shown in SNPs per site.

Fig 7. *Mycobacterium chimaera* global fastBAPS cluster phylogenies. Rooted maximum likelihood phylogenetic trees for A) *Mycobacterium chimaera* FB5 (n = 45); B) *Mycobacterium chimaera* FB6 (n = 765) and C) *Mycobacterium chimaera* FB6 with major clades collapsed; pie charts are shown for each major clade showing the distribution of sources for that clade. The taxa are clustered according to their sequence similarities. The lengths of the branches are scaled in nucleotide substitutions per site. The source of isolate, country of collection and study are shown as datastrips to the right of the phylogenies. Isolates from the Royal Brompton Hospital are highlighted in red. Branch lengths are shown in SNPs per site for *Mycobacterium chimaera* FB5.

Fig 8: *Mycobacterium chimaera* **fastBAPS cluster FB6 phylogenies.** Maximum

likelihood phylogenetic trees for A) FB6_FB1 (n = 540); B) FB6_FB2 (n = 186); and C)

FB6_FB4 (n = 34). The taxa are clustered according to their sequence similarities.

The lengths of the branches are scaled in nucleotide substitutions per site. The source

of isolate, country of collection and study are shown as datastrips to the right of the

phylogenies. Isolates from the Royal Brompton Hospital are highlighted in red.

Supplementary Material

Table A. Reference genomes used in this study.

Species/ subspecies	Reference	Length (Mb)	Country of isolation	Year(s) of isolation
M. intracellulare	ATCC 13950	5.4	South Korea	2012
M. avium subsp. *avium*	104	5.5	USA	1983

M. avium subsp. hominissuis	TH135	5.0	Japan	2004-2008
M. chimaera	DSM 44623	5.9	Italy	1999-2003

867 Table B. *Mycobacterium intracellulare* transmission clusters

fastBAPS cluster	Transmission cluster	Patients (n)	Bronchiectasis (n)	Cystic Fibrosis (n)	Other lung conditions (n)	No pre-existing lung condition (n)	Patients undergoing treatment (n)
Mi_FB2	Mi_FB2_1	2	0	2	0	0	1
Mi_FB3	Mi_FB3_1	16	8	7	1	0	4
Mi_FB5	Mi_FB5_1	3	2	0	1	0	2

870 Table C. *M. avium* subsp. *avium* transmission clusters

fastBAPS cluster	Transmission cluster	Patients (n)	Bronchiectasis (n)	Cystic Fibrosis (n)	Other lung conditions (n)	No pre-existing lung condition (n)	Patients undergoing treatment (n)

MAA_FB5	MAA_FB5_1	10	6	2	2	0	4
MAA_FB5	MAA_FB5_4	2	1	1	0	0	0
MAA_FB5	MAA_FB5_5	2	1	0	1	0	1
MAA_FB5	MAA_FB5_12	2	1	1	0	0	1
MAA_FB7	MAA_FB7_1	2	2	0	0	0	1
MAA_FB10	MAA_FB10_1	2	0	2	0	0	0
MAA_FB14	MAA_FB14_1	2	2	0	0	0	1

873   Table D. *M. avium* subsp. *hominissuis* transmission clusters

fastBAPS cluster	Transmission cluster	Patients (n)	Bronchiectasis (n)	Cystic Fibrosis (n)	Other lung conditions (n)	No pre-existing lung condition (n)	Patients undergoing treatment (n)

MAH_FB8	MAH_FB8_1	16	7	4	3	1	0
MAH_FB10	MAH_FB10_1	4	2	2	0	0	1
MAH_FB11	MAH_FB11_1	6	3	1	2	0	0
MAH_FB12	MAH_FB12_2	4	1	2	1	0	2
MAH_FB14	MAH_FB14_3	4	2	2	0	0	0
MAH_FB14	MAH_FB14_7	2	0	2	0	0	0
MAH_FB14	MAH_FB14_9*	7	3	2	1	0	1

875 Table E. *Mycobacterium chimaera* transmission clusters

fastBAPS cluster	Transmission cluster	Patients (n)	Bronchiectasis (n)	Cystic Fibrosis (n)	Other lung conditions (n)	No pre-existing lung condition (n)	Patients undergoing treatment (n)
Mc_FB3	Mc_FB3_1	106	43	24	25	3	15

Mc_FB3	Mc_FB3_3	2	1	1	0	0	0
Mc_FB3	Mc_FB3_4	2	2	0	0	0	0
Mc_FB3	Mc_FB3_6	2	1	0	1	0	0
Mc_FB3	Mc_FB3_13	4	1	1	1	1	1
Mc_FB3	Mc_FB3_16	2	0	0	1	1	1
Mc_FB3	Mc_FB3_17	2	1	1	0	0	0
Mc_FB3	Mc_FB3_19	2	0	1	0	1	0
Mc_FB3	Mc_FB3_25	2	1	1	0	0	1
Mc_FB3	Mc_FB3_30*	4	0	1	0	0	0
Mc_FB4	Mc_FB4_1	2	1	1	0	0	1
Mc_FB4	Mc_FB4_2	9	3	3	3	0	2
Mc_FB4	Mc_FB4_3*	6	1	2	2	0	1

877
878
879   Table F. *Mycobacterium chimaera* epidemiological links
880

Patients with epidemiological link	Hospital ward	Dates of overlapping stay
24/218	FOUL	02/02/12-12/02/12
163/218	FOUL	13/02/12
175/218	FOUL	05/04/12-16/04/12
130/218	LIND	30/04/12
76/218	FOUL	06/06/12-11/06/12
32/163	LIND	29/06/12
79/241	LIND	05/07/12
241/272	LIND	06/07/12
177/186	LIND	06/08/12
122/175/306	FOUL	25/10/12-30/10/12
30/122	FOUL	05/11/12-06/11/12
30/218	FOUL	12/11/12-13/11/12

882   Table G. *Mycobacterium chimaera* global transmission clusters containing RBH

883   isolates

fastBAPS cluster	Transmission cluster	Total isolates (n)	Patients (n)	HCU (n)	Other (n)
FB5	FB5_1	21	4	15	2

FB5	FB5_2	7	7	0	0
FB5	FB5_3	5	5	0	0
FB5	FB5_6	4	4	0	0
FB6_FB1	FB6_FB1_1	489	230	258	1
FB6_FB1	FB6_FB1_2	6	6	0	0
FB6_FB1	FB6_FB1_8	5	5	0	0
FB6_FB1	FB6_FB1_21	4	4	0	0
FB6_FB2	FB6_FB2_1	22	22	0	0
FB6_FB2	FB6_FB2_2	36	36	0	0
FB6_FB2	FB6_FB2_8	16	16	0	0
FB6_FB2	FB6_FB2_17	10	10	0	0
FB6_FB2	FB6_FB2_32	11	11	0	0
FB6_FB2	FB6_FB2_35	2	2	0	0
FB6_FB4	FB6_FB4_8	4	4	0	0
FB6_FB4	FB6_FB4_11	3	3	0	0
FB6_FB4	FB6_FB4_16	2	2	0	0

Fig A. Within-host isolate pairwise SNP diversity in fastBAPS lineages for A) *Mycobacterium intracellulare*; B) *Mycobacterium avium* subsp. *avium;* C) *Mycobacterium avium* subsp. *hominissuis* and D) *Mycobacterium chimaera*.

Fig B. Population structure of *Mycobacterium avium* at the Royal Brompton Hospital. Maximum likelihood phylogenetic tree of 406 *Mycobacterium avium* isolates rooted with a *Mycobacterium avium* subsp. *paratuberculosis* isolate (DRR263663). The subspecies of each isolate is shown in the datastrip to the right of the phylogeny. The scale bar is shown in SNPs per site.

Fig C. Global fastBAPS cluster pairwise SNP distance distributions. Boxplots

showing isolate pairwise SNP distances for A) *Mycobacterium intracellulare*; B)

Mycobacterium avium subsp. *avium* and C) *Mycobacterium avium* subsp. *hominissuis*

905 **Fig D: Distribution of pairwise SNP distances between isolates from the Royal**

906 **Brompton Hospital and other studies**. Histograms showing distribution of pairwise

907   SNP distances for fastBAPS clusters for A) *Mycobacterium avium* subsp. *avium*; B)

908   *Mycobacterium avium* subsp. *hominissuis* and C) *Mycobacterium chimaera*.